[City, State] – [Date] – Verastem Oncology is poised to accelerate the development of its novel KRAS G12D inhibitor, VS-7375, into late-stage clinical trials, following a compelling data readout from the ongoing TARGET-D 101 Phase I/II study. The drug has demonstrated significant clinical activity and a favorable safety profile across multiple difficult-to-treat solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small cell lung cancer (NSCLC). This promising performance, particularly at higher doses, has paved the way for strategic discussions with regulatory bodies and the design of pivotal Phase III studies.
Verastem’s Targeted Approach: A Dual ON/OFF Inhibitor for KRAS G12D
At the heart of Verastem’s strategy is VS-7375, an orally administered, dual ON/OFF inhibitor specifically designed to target the KRAS G12D mutation. This mutation is a significant driver in a substantial number of aggressive cancers, notoriously difficult to treat with existing therapies. Unlike inhibitors that target only one conformational state of the mutated protein, VS-7375’s unique mechanism of action allows it to bind to both the active and inactive forms of KRAS G12D. This dual binding approach is hypothesized to offer a more comprehensive and potent blockade of the oncogenic signaling pathway driven by this specific mutation.
The TARGET-D 101 trial has been instrumental in evaluating VS-7375 across various patient populations and treatment settings. The study has enrolled patients with advanced KRAS G12D-mutated solid tumors, allowing researchers to gather crucial efficacy and safety data. The initial findings, announced on October 14th, have been met with considerable optimism, with Verastem reporting "robust clinical activity with a favourable safety and tolerability profile." This positive assessment has directly informed the decision to escalate VS-7375 into more advanced stages of clinical development.
Chronology of Development: From Early Phase to Pivotal Studies
The journey of VS-7375 to this critical juncture represents a significant milestone in targeted cancer therapy. The progression from Phase I/II studies to planned Phase III trials underscores the confidence Verastem Oncology has garnered in the drug’s potential.
- Ongoing TARGET-D 101 Phase I/II Trial: This multi-cohort study has been the bedrock of VS-7375’s development, exploring its efficacy and safety in patients with KRAS G12D-mutated solid tumors. Data from various tumor types and treatment lines have been meticulously collected and analyzed.
- Data Readout and Strategic Alignment: The recent data readout from TARGET-D 101 provided the crucial evidence needed to advance VS-7375. Verastem has confirmed alignment with the U.S. Food and Drug Administration (FDA) on the design of a Phase III study for the first-line mPDAC setting.
- Future Milestones: Verastem has outlined ambitious plans for the near future, including meetings with the FDA before the end of 2026 to finalize Phase III pivotal trial designs for first-line metastatic colorectal cancer (mCRC) and first-line advanced non-small cell lung cancer (NSCLC). The company aims to open both of these trials for enrollment by the end of the first half of 2027.
This structured approach, characterized by early regulatory engagement and a clear roadmap for pivotal studies, signals Verastem’s commitment to expeditiously bringing this potentially life-changing therapy to patients.
Supporting Data: A Deep Dive into Clinical Activity and Molecular Responses
The promising clinical activity of VS-7375 has been most vividly demonstrated in the mPDAC cohort, where higher doses of the drug have yielded particularly encouraging results.
mPDAC: High-Dose Data Fuels Phase III Trial Advancement
In patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with VS-7375 at a dose of 900mg once daily (QD) as monotherapy, significant responses were observed. In the second-line (2L) setting for PDAC, the confirmed objective response rate (ORR) reached an impressive 50%. When evaluated in the 2L+ setting (including patients who had received prior therapies), the ORR was 41%. These figures include instances of complete responses (CR), with one confirmed and one unconfirmed CR noted. Furthermore, in the third-line (3L)/fourth-line (4L) setting, a confirmed ORR of 36% was achieved, indicating sustained efficacy even in heavily pre-treated patients.
Beyond response rates, the disease control rate (DCR) in the 2L+ setting was a robust 86%. Crucially, the six-month progression-free survival (PFS) rate stood at 67%, and the overall survival (OS) rate at six months was 80%. These metrics suggest that VS-7375 not only shrinks tumors but also helps patients live longer without their disease progressing.
The data from the 900mg QD monotherapy cohort proved superior to that observed at the 600mg dose, providing a strong rationale for advancing the 900mg dose in subsequent studies. This dose optimization is critical for maximizing therapeutic benefit while maintaining an acceptable safety profile.
Adding to the compelling clinical data, molecular responses observed in patients with pancreatic cancer have been particularly striking. Dr. Manuel Hidalgo, Director of the Gastrointestinal Cancer Center at New York University (NYU) Langone Health and an investigator in the TARGET-D 101 trial, highlighted the significance of these findings: "The clinical activity observed with VS-7375 is complemented by striking molecular responses in patients with pancreatic cancer, including deep reductions in KRAS G12D variant allele frequency and ctDNA clearance in more than half of the evaluable patients." The reduction in circulating tumor DNA (ctDNA) is a powerful indicator that the drug is effectively eliminating cancer cells throughout the body, potentially offering a more comprehensive measure of treatment success than imaging alone.
Benefit Also Seen in mCRC and NSCLC: Broad Applicability of VS-7375
The promise of VS-7375 extends beyond pancreatic cancer, with encouraging results also reported in metastatic colorectal cancer (mCRC) and advanced non-small cell lung cancer (NSCLC).
In patients with mCRC treated with the 900mg dose in the 3L setting, a 33% ORR was achieved when VS-7375 was used in combination with an anti-EGFR therapy. While the lower 600mg dose in combination showed a slightly lower response rate, a significant number of patients (14 out of 24) remained on treatment, suggesting potential long-term benefit. Verastem’s decision to advance with the 900mg dosing for these mCRC patients reinforces the dose-response trend observed in the study.
For patients with NSCLC, the 600mg QD monotherapy demonstrated a confirmed ORR of 43% in the 2L+ setting. Responses were observed relatively early, with some appearing as soon as six weeks into treatment. The six-month landmark PFS rate was a notable 72%, with the majority of patients continuing on therapy. These results indicate that VS-7375 can provide meaningful benefit for patients with advanced NSCLC. The higher 900mg QD dose is currently under evaluation in the TARGET-D 202 Phase II registration-directed trial for advanced NSCLC, a move that could potentially unlock even greater efficacy.
Furthermore, when investigated in the first-line setting as a triplet therapy, combining VS-7375 with standard of care (SoC) chemotherapy and immunotherapy in KRAS G12D-mutated lung adenocarcinoma, the ORR reached an impressive 75%. This high response rate in a first-line setting, particularly with a triplet combination, is a significant achievement and underscores the broad potential of VS-7375 in this challenging cancer type.
Across all tumor types and treatment settings evaluated in TARGET-D 101, both as monotherapy and in combination, VS-7375 consistently exhibited a favorable and manageable safety profile at both the 600mg and 900mg dose levels. This is a critical factor for sustained treatment and patient quality of life.
Official Responses and Regulatory Engagement
The positive data readout has prompted swift action and strategic planning from Verastem Oncology. The company’s proactive engagement with regulatory bodies, particularly the U.S. Food and Drug Administration (FDA), is a testament to their commitment to advancing VS-7375 through the development pipeline.
The alignment with the FDA on the Phase III study design for the first-line mPDAC setting is a significant de-risking event. This collaborative approach ensures that the planned pivotal trial will meet regulatory expectations, potentially streamlining the path to market approval. Verastem’s intention to meet with the FDA before the end of 2026 to discuss Phase III pivotal trial designs for first-line mCRC and first-line advanced NSCLC further demonstrates their commitment to a comprehensive development program. The ambitious timeline for opening these trials by the end of H1 2027 underscores the urgency and optimism surrounding VS-7375.
The company has also indicated that more data will be forthcoming in the coming months. This includes more mature data from the TARGET-D 101 mCRC 900mg combination cohort and initial data from the 600mg combination arm by the end of 2026. This ongoing data generation will provide further insights into the drug’s performance and solidify the foundation for the pivotal studies.
Implications for the Oncology Landscape: Targeting a Difficult Mutation
The advancement of VS-7375 into late-stage studies carries significant implications for the broader oncology landscape, particularly in the fight against KRAS-mutated cancers. KRAS mutations, once considered "undruggable," are now a major focus of drug development, and VS-7375’s success could represent a paradigm shift.
- Addressing Unmet Needs: KRAS G12D is a particularly challenging mutation, frequently found in aggressive cancers like mPDAC, mCRC, and NSCLC. Current treatment options for patients with these mutations are often limited, and survival rates can be poor. A targeted therapy like VS-7375 offers a much-needed beacon of hope.
- Competitive Landscape: Verastem is not alone in pursuing KRAS inhibition. Several other pharmaceutical giants are also investing heavily in this area. MSD’s calderasib, an oral covalent inhibitor, is in late-stage studies for NSCLC and mCRC. Eli Lilly’s olomorasib is also progressing through Phase III trials in NSCLC. Furthermore, Roche’s subsidiary Genentech is conducting late-stage studies of divarasib in NSCLC. The success of VS-7375 will be a critical factor in this evolving competitive space.
- NSCLC as a Key Indication: NSCLC remains a primary battleground for KRAS-targeting therapies. With KRAS being the most common oncogenic driver mutation in NSCLC, accounting for approximately 25% to 30% of all NSCLC cases (specifically in lung adenocarcinoma), the potential market for effective KRAS inhibitors is substantial.
- Pancreatic and Colorectal Cancers: mPDAC and mCRC are also primary areas where pan-RAS inhibitors and KRAS G12D-specific drugs are expected to make a significant impact. The high unmet need in these diseases makes any promising development particularly noteworthy.
Verastem Oncology’s VS-7375, with its unique dual ON/OFF inhibition mechanism and promising clinical data, is positioned to potentially carve out a significant role in the treatment of KRAS G12D-mutated cancers. The transition to Phase III trials marks a pivotal moment, bringing the prospect of a new therapeutic option for patients facing some of the most challenging forms of cancer closer to reality. The coming years will be critical in determining the ultimate impact of VS-7375 on patient outcomes and the broader landscape of precision oncology.
About the Author
